Nobias Therapeutics is advancing NB-001, a novel therapeutic for 22q11.2 Deletion Syndrome (22q11DS), currently in Phase II clinical trials. This syndrome, also known as DiGeorge syndrome, affects approximately 1 in 4,000 live births and is characterized by a variety of physical and neurodevelopmental issues.
Novel Mechanism of Action
NB-001 is designed as a non-stimulant activator of multiple metabotropic glutamate receptors (mGluRs). This mechanism aims to address the underlying neurobiological deficits associated with 22q11DS, offering a potential improvement over existing symptomatic treatments.
Clinical Development and Trial Results
Clinical trials have demonstrated the safety and tolerability of NB-001. The multi-center, randomized, placebo-controlled crossover trial provided evidence supporting further investigation into its efficacy. The drug is administered orally, making it a convenient option for patients.
Addressing Comorbid Psychiatric Conditions
Beyond the core symptoms of 22q11DS, NB-001 targets common comorbid psychiatric conditions such as anxiety, attention-deficit/hyperactivity disorder (ADHD), and autism spectrum disorder (ASD). These conditions significantly impact the quality of life for individuals with 22q11DS and their families.
Current Treatment Landscape and Unmet Needs
Currently, treatments for 22q11DS primarily focus on managing individual symptoms through various therapies and interventions. There is a significant unmet need for treatments that address the underlying causes and associated psychiatric conditions. NB-001 represents a promising approach to fulfill this need.
